A Phase II Study of Dexamethasone Added to Induction and Post-remission Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
- 试验地点
- 25
- 主要终点
- Event Free survival (EFS)
研究概览
简要总结
Recent preclinical and clinical data strongly suggested that dexamethasone could improve the activity of intensive chemotherapy in AML. In this study, the FILO study group will assess the impact of adding dexamethasone to both induction and consolidation therapy in older AML patients with intermediate or favorable risk.
详细描述
Patients will receive dexamethasone in addition to induction and post-remission chemotherapy
The principal objective of the study is to determine whether adding dexamethasone to induction and post-remission therapy results in significant improvement of event-free survival (EFS) as compared with an historical cohort of the FILO LAM-SA 2007 trial.
Induction therapy: Idarabucin + Cyrarabine + Lomustine (ICL) + Dexamethasone. Idarubicin 8 mg/m²/day, IV over 15 minutes, D1 to D5; Cytarabine 100 mg/m²/d, IV continuous 24h-infusion D1 to D7; Lomustine 200 mg/m²/d, orally at D1; Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3.
Post remission therapy: Idarabucin + Cyrarabine (IC) + Dexamethasone
Idarubicin 8 mg/m², IV over 15 minutes, D1; Cytarabine 50 mg/m²/12h, subcutaneous, D1 to D5; Dexamethasone 20 mg/d, IV over 30 minutes, D1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •> 60 years of age.
- •Newly diagnosed AML according to the World Health Organization (WHO) 2016 either de novo AML or therapy-related AML (i.e AML arising after previous cytotoxic therapy or radiation)
- •AML with favorable or intermediate cytogenetic risk according to Medical Research Council (MRC 2010) classification.
- •Subjects should be eligible for intensive chemotherapy by Idarubicin, cytarabine, Lomustine.
- •Eastern Cooperative Oncology Group (ECOG) performance status < 3 (appendix 1).
- •SORROR score ≤ 3 (appendix 2).
- •Adequate baseline organ function defined by the criteria below:
- •Total bilirubin ≤ 1.5 x Upper Limit of Normal (ULN) unless bilirubin rise is due to Gilbert's syndrome
- •Alanine Aminotransferase (ALAT) and Aspartate Transaminase (ASAT) ≤ 3xULN
- •creatinin clearance (Cockcroft-Gault) ≥ 30 ml/min
- •Unless considered due to leukemic organ involvement
- •Adequate cardiac function with Left Ventricular Ejection Fraction (LVEF) ≥50%
- •Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
- •Women will be menopausal to be enrolled
- •The patient must give written (personally signed and dated) informed consent before completing any study-related procedure which means assessment or evaluation that would not form part of the normal medical care of the patient and before the start of induction chemotherapy.
- •Affiliated to the French Social Security (Health Insurance).
排除标准
- •Acute promyelocytic leukemia (APL) or acute megakaryocytic leukemia (AML-FAB M7).
- •AML with adverse cytogenetic risk according to the MRC 2010 classification.
- •AML arising from myelodysplastic syndromes, myeloproliferative disorders or chronic myelo-monocytic leukemia according to WHO classification (2016).
- •AML with Philadelphia chromosome or with BCR-ABL
- •Known active central nervous system leukemia
- •Previous anti-AML treatment other than hydroxyurea.
- •Cumulative anthracycline dose equivalent to ≥550 mg/m².
- •Treatment with an investigational drug within 30 days or 5 half-life whichever is longer, preceding the first dose of study medication.
- •Prior history of cancer unless controlled for at least 2 years and except for basal cell carcinoma, non-melanoma skin cancer and in situ cervical carcinoma.
- •Severe medical or mental condition precluding the administration of protocol treatments
- •Any sign of active uncontrolled disease including but not restricted to cardiac disease, infections, hepatitis.
- •Any severe chronic disease potentially interfering with the protocol including HIV infection, active hepatitis B or C.
- •Any severe conditions inducing contra-indications to dexamethasone including uncontrolled diabetes, infections, hypertension, stomach ulcer, mental illness, myasthenia or glaucoma.
- •Any serious medical condition, laboratory abnormality, or psychiatric illness that would place the participant at an unacceptable risk or prevent them from giving informed consent.
- •Known active HIV, Hepatitis B or C infection.
- •Pregnancy or breastfeeding.
- •Patients who are incapacitated, under wardship, legal guardianship, or under the protection of the courts.
- •Patients under State Medical Assistance (AME).
研究组 & 干预措施
DEXAML
Induction therapy:
Idarubicin 8 mg/m²/day, IV over 15 minutes, D1 to D5 + Cytarabine 100 mg/m²/d, IV continuous 24h-infusion D1 to D7 + Lomustine 200 mg/m²/d, orally at D1 + Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3. Addition of midostaurin in patients with Fms-like tyrosine kinase 3-internal tandem ( FLT3-ITD) or Fms-like tyrosine kinase 3-tyrosine kinase domain (FLT3-TKD) mutations is allowed.
Post remission therapy:
Idarubicin 8 mg/m², IV over 15 minutes, D1 + Cytarabine 50 mg/m²/12h, subcutaneous, D1 to D5 + Dexamethasone 20 mg/d, IV over 30 minutes, D1. Addition of midostaurin in patients with FLT3-ITD or FLT3-TKD mutations is allowed. Intermediate dose cytarabine is allowed for patients with Core Binding Factor AML (CBF-AML).
Allogeneic stem-cell transplantation allowed after 2 to 4 cycles
干预措施: Dexamethasone (Drug)
结局指标
主要结局
Event Free survival (EFS)
时间窗: Within 2 years after the start of the Treatement
Time from the date of induction start to the date of induction failure, relapse from CR or CRi, or death from any cause, whichever occurs first. CR, CRi, relapse from CR or CRi and induction failure are defined according to the ELN 2017 recommendations
次要结局
- Treatment response(Up to 45 day)
- Remission duration (relapse from CR or CRi)(two years)
- Minimal Residual Disease (MRD)(Up to day 45 after induction chemotherapy, second and last consolidation cycle.)
- Allogenic Stem Cells Transplantation (ASCT)(Up to one year)
- Relapse Free Survival (RFS)(two years)
- Adverse events(up to 60 months)
- Overall Survival (OS)(two years)